Paion AG (PA8) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
55
About the Report
About the Report
Summary
Paion AG (Paion) is a specialty pharmaceutical company that focuses on the development and commercialization of drugs used for out-patient and hospital-based sedation, anesthesia and critical care services. The company's lead product, remimazolam, is designed for the treatment of patients requiring sedation. Paion currently develops remimazolam for general anesthesia. The company completed clinical development program for general anesthesia in Japan and initiated a Phase 3 trial in the European Union. It has presence in the UK, the US and Germany. Paion is headquartered in Aachen, Germany.
Paion AG (PA8)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Paion AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Paion AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Paion AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Paion AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Paion AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Paion AG, Medical Devices Deals, 2012 to YTD 2018 10
Paion AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Paion AG, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Paion Raises USD 4.8 Million In Venture Financing 12
Licensing Agreements 13
Mundipharma Enters into Licensing Agreement with Paion 13
Cosmo Pharma Enters into Licensing Agreement with Paion for Remimazolam 14
Paion Enters into Licensing Agreement with Yichang Humanwell for M6G 15
Paion Exercises Option for Licensing Agreement with PendoPharm for Remimazolam 16
Paion Extends Licensing Agreement with R-Pharm for Remimazolam for MENA Region 17
Paion Enters Into Licensing Agreement With R-Pharm For Remimazolam 18
Paion Extends Licensing Agreement With R-Pharm For Remimazolam 19
Paion Exercises Option for Licensing Agreement with Hana Pharma for Remimazolam 20
Yichang Humanwell Pharma Exercises Option with Paion to License Remimazolam 21
Equity Offering 23
Paion to Raise USD6 Million in Private Placement of Shares 23
Paion Raises USD9.2 Million in Private Placement of Shares 24
Paion to Raise USD5.3 Million in Rights Offering 25
Paion Raises USD10.9 Million in Private Placement of Shares 26
Paion Raises USD5.4 Million in Private Placement of Shares 27
Paion Raises USD61.3 Million in Rights Offering of Shares 28
Paion Raises USD1.4 Million in Private Placement of Shares 29
Paion Completes Private Placement of Shares for USD8.5 Million 30
Paion Completes Private Placement Of Shares For USD 8.4 Million 31
Paion Completes Rights Offering of Shares for USD6.86 Million 32
Asset Transactions 33
Lundbeck Acquires Desmoteplase, Ischaemic Stroke Drug From Paion For USD 27 Million 33
Paion AG-Key Competitors 35
Paion AG-Key Employees 36
Paion AG-Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Financial Announcements 38
Aug 08, 2018: Paion reports financial results for the first half-year 2018 38
Mar 22, 2018: PAION reports on fiscal year and financial results 2017 41
Nov 08, 2017: Paion Publishes Group Quarterly Statement For The First Nine Months Of 2017 44
Aug 09, 2017: PAION reports financial results for the first half-year of 2017 47
Mar 16, 2017: PAION reports on fiscal year and financial results 2016 50
Product Approvals 53
Nov 14, 2017: FDA Considers Current Human Abuse Liability Program with Remimazolam in the U.S. As Sufficient; no Second Intranasal Study Required 53
Clinical Trials 54
Nov 23, 2017: PAION Announces Clinical Development Progress with Remimazolam by its Partner Hana Pharma in South Koera 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55
List of Figure
List of Figures
Paion AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Paion AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Paion AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Paion AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Paion AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Paion AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Paion AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Paion AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Paion AG, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Paion AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Paion AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Paion AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Paion AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Paion AG, Deals By Therapy Area, 2012 to YTD 2018 9
Paion AG, Medical Devices Deals, 2012 to YTD 2018 10
Paion AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Paion Raises USD 4.8 Million In Venture Financing 12
Mundipharma Enters into Licensing Agreement with Paion 13
Cosmo Pharma Enters into Licensing Agreement with Paion for Remimazolam 14
Paion Enters into Licensing Agreement with Yichang Humanwell for M6G 15
Paion Exercises Option for Licensing Agreement with PendoPharm for Remimazolam 16
Paion Extends Licensing Agreement with R-Pharm for Remimazolam for MENA Region 17
Paion Enters Into Licensing Agreement With R-Pharm For Remimazolam 18
Paion Extends Licensing Agreement With R-Pharm For Remimazolam 19
Paion Exercises Option for Licensing Agreement with Hana Pharma for Remimazolam 20
Yichang Humanwell Pharma Exercises Option with Paion to License Remimazolam 21
Paion to Raise USD6 Million in Private Placement of Shares 23
Paion Raises USD9.2 Million in Private Placement of Shares 24
Paion to Raise USD5.3 Million in Rights Offering 25
Paion Raises USD10.9 Million in Private Placement of Shares 26
Paion Raises USD5.4 Million in Private Placement of Shares 27
Paion Raises USD61.3 Million in Rights Offering of Shares 28
Paion Raises USD1.4 Million in Private Placement of Shares 29
Paion Completes Private Placement of Shares for USD8.5 Million 30
Paion Completes Private Placement Of Shares For USD 8.4 Million 31
Paion Completes Rights Offering of Shares for USD6.86 Million 32
Lundbeck Acquires Desmoteplase, Ischaemic Stroke Drug From Paion For USD 27 Million 33
Paion AG, Key Competitors 35
Paion AG, Key Employees 36
Paion AG, Subsidiaries 37
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.